The ONE CANCER PLACE NewsRoom provides patients with quick access to exclusive news, treatment breakthroughs, survivor stories, and expert interviews providing the latest insight about this rapidly evolving industry. Visit our NewsRoom often and follow us on Facebook.

Breast Cancer Patient Stories Plus Stats On Genetic Stats
October is breast cancer awareness month, so we're shedding light on this particular type of cancer. Aside from skin cancers, breast cancer is the most common type of cancer women...

5 Changes To Make To Your Outdoor Space During Cancer Treatment
Since you are here reading this, most likely you or your dear ones might be suffering from cancer or its side effects. Some of you might already know that cannabinoids...

Colon Cancer Patient Stories Plus Prevention, Signs & Symptoms
A new Colon Cancer version of SURVIVEiT®'s Cancer Navigation Tool has just been released for colon cancer patients, caregivers and survivors. Our 5-step personalized planning tool was created by cancer...

Interview with the Executive Director of Harmony Hill
Facing cancer can leave cancer patients feeling isolated from the rest of the world. That's why we encourage patients and caregivers to find a community of others who are going...

The Cancer Liberation Project Podcast
Hayley Dubin is an ovarian cancer survivor and a member of SURVIVEiT 's Survivor Advisory Council. This Summer Hayley launched her very own podcast, The Cancer Liberation Project, exploring liberation...

8 Changes To Make To Your Bedroom During Cancer Treatment
Going through cancer treatment can be a challenging time, so we've put together a list of changes you can make to your bedroom to help ease the process and side...

FDA approves nivolumab for adjuvant treatment of urothelial carcinoma
FDA approves nivolumab for adjuvant treatment of urothelial carcinoma On August 19, 2021, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Co.) for the adjuvant treatment of patients...

FDA grants accelerated approval to dostarlimab-gxly for dMMR advanced solid tumors
FDA grants accelerated approval to dostarlimab-gxly for dMMR advanced solid tumors On August 17, 2021, the Food and Drug Administration granted accelerated approval to dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) for adult...